Table 1.
Clinical characteristics of this study and TCGA cohorts
| Characteristics | This study | TCGA | P-value | ||
|---|---|---|---|---|---|
| All (N = 151) | Training (N = 92) | Validation (N = 49) | All (N = 91) | ||
| Age(years) | |||||
| < 65 | 86(57.0%) | 55(59.8%) | 26(53.1%) | 41(45.1%) | 0.08 |
| ≥ 65 | 65(43.0%) | 37(40.2%) | 23(46.9%) | 50(54.9%) | |
| Gender | |||||
| Male | 76(50.3%) | 49(53.3%) | 22(44.9%) | 49(53.8%) | 0.69 |
| Female | 75(49.7%) | 43(46.7%) | 27(55.1%) | 42(46.2%) | |
| Stage (AJCC 7th) | |||||
| I-II | 121(80.1%) | 82(89.1%) | 39(79.6%) | 87(95.6%) | < 0.01 |
| III | 22(14.6%) | 10(10.9%) | 12(24.5%) | 3(3.3%) | |
| IV | 8(5.3%) | 0(0%)a | 0(0%)a | 1(1.1%) | |
| Pathology T stage | |||||
| T1-2 | 5(3.3%) | 2(2.2%) | 3(6.1%) | 11(12.1%) | 0.01 |
| T3-4 | 146(96.7%) | 90(97.8%) | 46(93.9%) | 80(87.9%) | |
| Pathology N stage | |||||
| N0 | 42(27.8%) | 27(29.3%) | 15(30.6%) | 14(15.4%) | 0.04 |
| N1-2 | 109(72.2%) | 65(70.7%) | 34(69.4%) | 77(84.6%) | |
| Neoplasm histologic grade | |||||
| G1-2 | 120(79.5%) | 84(91.3%) | 31(63.3%) | 47(51.6%) | 8.01E-6 |
| G3 | 31(20.5%) | 8(8.7) | 18(36.7%) | 44(48.4%) | |
| Surgical margin resection status | |||||
| R0 | 50(33.1%) | 28(30.4%) | 18(36.7%) | 49(53.8%) | 1.36E-5 |
| R1 + R2 | 99 + 2(66.9%) | 64(69.6%) | 31(63.3%) | 37(40.7%) | |
| Rx/NA | 0(%) | 0(%) | 0(%) | 5(5.5%) | |
| Vascular invasion | |||||
| Negative | 86(57.0%) | 55(59.8%) | 27(55.1%) | - | |
| Positive | 65(43%) | 37(40.2%) | 22(44.9%) | - | |
| Perineural invasion | |||||
| Negative | 14(9.3%) | 4(4.3%) | 7(14.3%) | - | |
| Positive | 137(90.7%) | 88(95.7%) | 42(85.7%) | - | |
a10 stage IV patients were excluded from prediction modeling